Cannbit pharmaceuticals is a public company, acquired Israeli medical cannabis pioneer, Tikun Olam in 2019. Tikun Olam-Cannbit LTD. is a leading supplier on the local market. Since its establishment, the company has treated more than 30,000 patients in Israel. From childhood through to old age, patients with a variety of medical conditions have received treatment from the company’s experience worldwide in the treatment of patients and have alleviated their suffering through medical cannabis. Cannbit pharmaceuticals operates throughout the entire value chain while maintaining an ecosystem that integrates values of sustainability, therapeutic continuity, and uniformity in the quality of its products. Cannbit has production facility in the north of Israel and cultivation farm at the Dead Sea were received the EU-GMP certification. Patients are at the core of the our hearts, minds, planning and action, and a unique system of care has been built for years around them. Thanks to our long-years experience and pharmaceutical approach, Cannbit is endorsed by the leading health insurers, medical institutes of Israel, and by healthcare professional. We formed a one of a kind ecosystem which includes research and clinical trials, genetic R&D for development of unique strains tailor-made for real medical needs, cultivation and propagation farms, a production facility, an advanced laboratory and technological R&D site, a logistics center, a dispensary and direct delivery to the customer’s home, as well as a service and pharma system that includes patient training and counselling, via our caring qualified nurses while maintaining a personalized treatment sequence.